4.5 Article

DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail

Journal

CANCER SCIENCE
Volume 110, Issue 5, Pages 1599-1608

Publisher

WILEY
DOI: 10.1111/cas.13997

Keywords

delta-like protein 3; migration; NOTCH; small cell lung cancer; SNAI1

Categories

Ask authors/readers for more resources

Delta-like protein 3 (DLL3) is a ligand of Notch signaling, which mediates cell-fate decisions and is tumor-suppressive or oncogenic depending on the cellular context. Previous studies show that DLL3 is highly expressed in small cell lung cancer (SCLC) but not in normal lung tissue, suggesting that DLL3 might be associated with neuroendocrine tumorigenesis. However, its role in SCLC remains unclear. To investigate the role of DLL3 in tumorigenesis in SCLC, we performed loss-of-function and gain-of-function assays using SCLC cell lines. In vitro analysis of cell migration and invasion by transwell assay showed that DLL3 knockdown reduced migration and invasion of SCLC cells, whereas DLL3 overexpression increased these activities. In addition, DLL3 positively regulated SNAI1 expression and knockdown of SNAI1 attenuated the migration and invasion ability of SCLC cells. Moreover, upregulated DLL3 expression induced subcutaneous tumor growth in mouse models. These results indicate that DLL3 promoted tumor growth, migration and invasion in an SCLC model by modulating SNAI1/Snail.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer

Hirofumi Takahashi, Jun Sakakibara-Konishi, Megumi Furuta, Tetsuaki Shoji, Kosuke Tsuji, Daisuke Morinaga, Eiki Kikuchi, Junko Kikuchi, Takuro Noguchi, Kanako C. Hatanaka, Yutaka Hatanaka, Naofumi Shinagawa, Satoshi Konno

Summary: Notch pathway may be involved in the development of osimertinib resistance in EGFR-mutated NSCLC patients, and the combination of Notch inhibitors and osimertinib may be a potential therapeutic approach.

CANCER SCIENCE (2023)

No Data Available